Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101, Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575.
While PT-141 works as the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101, Retatrutide is a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575.
PT-141
POMC
Retatrutide
Not assigned in the current dataset.
PT-141 and Retatrutide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: PT-141 is more often discussed in the realm of Reproductive health, whereas Retatrutide is more often associated with the realm of Metabolic and endocrine. They also influence different molecular systems, with PT-141 tracking more closely to GPCR receptor while Retatrutide centers more on GLP-1 receptor. Both are synthetic in origin and their development context also differs, with PT-141 approved while Retatrutide is in Clinical phase 3. PT-141 takes the form of a cyclic peptide, whereas Retatrutide is closer to a peptide conjugate, PT-141 carries acetylation features, while Retatrutide instead reflects lipidation changes; while their sequence patterns also diverge, with PT-141 showing protein-mimetic sequence features and Retatrutide showing alpha-helical domain features.